Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer
Our analysis revealed that although symptomatic individuals who underwent CDK4/6 inhibitor plus ET experienced a significant reduction in mPFS durations compared to asymptomatic patients, the 22-month mPFS indicated that CDK4/6 inhibitor plus ET is an effective treatment option.
Authors
- Alper Türkel (ORCID: https://orcid.org/0000-0001-5071-9679)
- Cengiz Karaçin (ORCID: https://orcid.org/0000-0002-7310-9328)
- Hicran Anık (ORCID: https://orcid.org/0009-0001-7992-4008)
- Ülkü Yalçıntaş Arslan (ORCID: https://orcid.org/0000-0001-5279-0903)
- İrem Öner (ORCID: https://orcid.org/0000-0001-9486-6187)
Institutions
- Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1080/14796694.2024.2432850
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00